These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 16460134)

  • 21. The rate, pattern, and cost of use of antiparkinsonian agents among patients treated for schizophrenia in a managed care setting.
    Ascher-Svanum H; Kennedy JS; Lee D; Haberman M
    Am J Manag Care; 2004 Jan; 10(1):20-4. PubMed ID: 14738183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective.
    Percudani M; Barbui C; Tansella M
    Pharmacoeconomics; 2004; 22(11):701-18. PubMed ID: 15250749
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies.
    Tunis SL; Johnstone BM; Kinon BJ; Barber BL; Browne RA
    Value Health; 2000; 3(3):232-42. PubMed ID: 16464187
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.
    Loosbrock DL; Zhao Z; Johnstone BM; Morris LS
    J Ment Health Policy Econ; 2003 Jun; 6(2):67-75. PubMed ID: 14578539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hospitalization risk associated with typical and atypical antipsychotic use in community-dwelling elderly patients.
    Aparasu RR; Jano E; Johnson ML; Chen H
    Am J Geriatr Pharmacother; 2008 Oct; 6(4):198-204. PubMed ID: 19028375
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimation of antipsychotic effects on hospitalization risk in a naturalistic study with selection on unobservables.
    Salkever DS; Slade EP; Karakus M; Palmer L; Russo PA
    J Nerv Ment Dis; 2004 Feb; 192(2):119-28. PubMed ID: 14770056
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
    Rascati KL; Johnsrud MT; Crismon ML; Lage MJ; Barber BL
    Pharmacoeconomics; 2003; 21(10):683-97. PubMed ID: 12828491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of atypical antipsychotics on quality of life in patients with schizophrenia.
    Awad AG; Voruganti LN
    CNS Drugs; 2004; 18(13):877-93. PubMed ID: 15521791
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH; Goa KL
    Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of atypical antipsychotic medications on psychosocial outcomes.
    Corrigan PW; Reinke RR; Landsberger SA; Charate A; Toombs GA
    Schizophr Res; 2003 Sep; 63(1-2):97-101. PubMed ID: 12892863
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia.
    Rothbard AB; Kuno E; Foley K
    Schizophr Bull; 2003; 29(3):531-40. PubMed ID: 14609246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Quetiapine : A Review of its Use in Schizophrenia.
    Gunasekara NS; Spencer CM
    CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What do large scale studies of medication in schizophrenia add to our management strategies?
    Agius M; Davis A; Gilhooley M; Chapman S; Zaman R
    Psychiatr Danub; 2010 Jun; 22(2):323-8. PubMed ID: 20562774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone.
    Nightengale BS; Crumly JM; Liao J; Lawrence BJ; Jacobs EW
    Psychopharmacol Bull; 1998; 34(3):373-82. PubMed ID: 9803771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
    Rosenheck RA; Leslie DL; Sindelar J; Miller EA; Lin H; Stroup TS; McEvoy J; Davis SM; Keefe RS; Swartz M; Perkins DO; Hsiao JK; Lieberman J;
    Am J Psychiatry; 2006 Dec; 163(12):2080-9. PubMed ID: 17151158
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
    JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.